BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2009 related articles for article (PubMed ID: 29285605)

  • 1. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
    Song GG; Lee YH
    Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Clin Rheumatol; 2016 Jul; 35(7):1795-803. PubMed ID: 26852316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
    Ungprasert P; Thongprayoon C; Davis JM
    Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis.
    Ruyssen-Witrand A; Perry R; Watkins C; Braileanu G; Kumar G; Kiri S; Nott D; Liu-Leage S; Hartz S; Sapin C
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32094304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.
    Betts KA; Griffith J; Friedman A; Zhou ZY; Signorovitch JE; Ganguli A
    Curr Med Res Opin; 2016; 32(4):721-9. PubMed ID: 26743448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis.
    Wu D; Yue J; Tam LS
    Rheumatology (Oxford); 2018 Mar; 57(3):563-571. PubMed ID: 29244162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fourteen small molecule and biological agents for psoriatic arthritis: A network meta-analysis of randomized controlled trials.
    Qiu M; Xu Z; Gao W; Xiong M; Wen X; Zhu W; Zhou X; Yu M
    Medicine (Baltimore); 2020 Jul; 99(31):e21447. PubMed ID: 32756163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
    Pham PA; Dressler C; Eisert L; Nast A; Werner RN
    Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological DMARD efficacy in psoriatic arthritis: a systematic literature review and meta-analysis on articular, enthesitis, dactylitis, skin and functional outcomes.
    Simons N; Degboé Y; Barnetche T; Cantagrel A; Ruyssen-Witrand A; Constantin A
    Clin Exp Rheumatol; 2020; 38(3):508-515. PubMed ID: 31969228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.